{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:53:21Z","timestamp":1769525601192,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T00:00:00Z","timestamp":1618704000000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.retram.2019.10.001","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:27:31Z","timestamp":1571300851000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Lionet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.retram.2019.10.001_bib0005","first-page":"1","article-title":"Immunomagnetic selective donor-derived CD4(+)CCR7(+) T cell depletion procedure for peripheral blood stem cells graft","volume":"67","author":"Varlet","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.retram.2019.10.001_bib0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood-2016-09-738625","article-title":"A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD","volume":"129","author":"Socie","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.transci.2015.02.001","article-title":"Extracorporeal photopheresis in prevention and treatment of acute GVHD","volume":"52","author":"Kitko","year":"2015","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-Host disease in allogeneic transplantation \u2013 a report from CIBMTR","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.retram.2019.10.001_bib0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/01.TP.0000173995.18826.DE","article-title":"Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies","volume":"80","author":"Bay","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.retram.2019.10.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0511-7","article-title":"Donor-derived CD4(+)\/CCR7(+) T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide","author":"Varlet","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.retram.2019.10.001_bib0035","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2019.10.001_bib0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2019.10.001_bib0045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"issue":"236","key":"10.1016\/j.retram.2019.10.001_bib0050","article-title":"Extracorporeal photopheresis\u2014an overview","volume":"5","author":"Cho","year":"2018","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1054\/blre.2001.0155","article-title":"Extracorporeal photopheresis: a review","volume":"15","author":"Oliven","year":"2001","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society","volume":"177","author":"Alfred","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.retram.2019.10.001_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2009.02.039","article-title":"Extracorporeal photopheresis: past, present, and future","volume":"61","author":"Knobler","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.retram.2019.10.001_bib0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1473-0502(02)00100-3","article-title":"Extracorporeal photopheresis technical aspects","volume":"28","author":"Schooneman","year":"2003","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.retram.2019.10.001_bib0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.patbio.2014.02.013","article-title":"The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: relationship between infused donor CD4+\/CCR7+ T cell subsets and acute graft-versus-host disease","volume":"62","author":"Choufi","year":"2014","journal-title":"Pathologie-biologie"},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/bmt.2014.244","article-title":"Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"50","author":"Detrait","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1 Suppl","key":"10.1016\/j.retram.2019.10.001_bib0085","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.bbmt.2011.10.021","article-title":"Fibrotic and Sclerotic Manifestations of Chronic Graft Versus Host Disease","volume":"18","author":"Kitko","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.retram.2019.10.001_bib0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jca.21357","article-title":"Biological quality control for extracorporeal photochemotherapy: assessing mononuclear cell apoptosis levels in ECP bags of chronic GvHD patients","volume":"30","author":"Taverna","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.retram.2019.10.001_bib0095","first-page":"105","article-title":"Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD","volume":"9","author":"Zhang","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"25","key":"10.1016\/j.retram.2019.10.001_bib0100","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2013-05-494278","article-title":"Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD","volume":"122","author":"Olivieri","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2019.10.001_bib0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0110","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/icvts\/ivv122","article-title":"Imatinib for sclerodermatous graft-versus-host disease in lung transplantation","volume":"21","author":"Zhang","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"11","key":"10.1016\/j.retram.2019.10.001_bib0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.252","article-title":"Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD","volume":"42","author":"Magro","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.retram.2019.10.001_bib0120","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2015.03.006","article-title":"Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease","volume":"21","author":"Baird","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.retram.2019.10.001_bib0125","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbmt.2011.04.002","article-title":"A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change","volume":"17","author":"Mitchell","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.retram.2019.10.001_bib0130","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.retram.2019.10.001_bib0135","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41409-018-0166-9","article-title":"Cytotect(R)CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study","volume":"53","author":"Alsuliman","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2019.10.001_bib0140","first-page":"557","article-title":"Clinical \u201ccase series\u201d: a concept analysis","volume":"12","author":"Abu-Zidan","year":"2012","journal-title":"Afr Health Sci"},{"issue":"17","key":"10.1016\/j.retram.2019.10.001_bib0145","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1182\/blood-2009-07-231159","article-title":"Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease","volume":"114","author":"Stadler","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2019.10.001_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-Host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2019.10.001_bib0155","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1100\/2011\/924954","article-title":"Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside","volume":"11","author":"Olivieri","year":"2011","journal-title":"Sci World J"},{"issue":"3","key":"10.1016\/j.retram.2019.10.001_bib0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3325\/cmj.2016.57.247","article-title":"Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease","volume":"57","author":"S\u00e1nchez-Ortega","year":"2016","journal-title":"Croat Med J"},{"issue":"10","key":"10.1016\/j.retram.2019.10.001_bib0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41409-018-0158-9","article-title":"Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib","volume":"53","author":"van der Wagen","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.retram.2019.10.001_bib0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.retram.2019.10.001_bib0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620717741860","article-title":"New and emerging therapies for acute and chronic graft versus host disease","volume":"9","author":"Hill","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.retram.2019.10.001_bib0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.retram.2019.10.001_bib0185","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.retram.2019.10.001_bib0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.0022-202X.2005.23859.x","article-title":"Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis","volume":"125","author":"Santiago","year":"2005","journal-title":"J Invest Dermatol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318619300418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318619300418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:38:09Z","timestamp":1762821489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318619300418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S2452318619300418"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2019.10.001","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2019.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}